News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi (France) (SAN.PA) Halves Price of Cancer Drug After Rejection From Cancer Center


11/9/2012 8:04:28 AM

In an unusual move, a big drug company said it would effectively cut in half the price of a new cancer drug after a leading cancer center said it would not use the drug because it was too expensive. The move — announced Thursday by Sanofi for the colon cancer drug Zaltrap — could be a sign that the marketplace is becoming resistant to the unfettered increase in the prices of cancer drugs over the past decade. Some of the newest cancer drugs cost more than $100,000 a year and increase survival by a few months at best. Zaltrap came to market in August at a price of about $11,000 a month. Soon afterward, the prestigious Memorial Sloan-Kettering Cancer Center in New York decided not to use the drug, saying it was twice as expensive but no more effective than a similar medicine, Avastin from Genentech. Both drugs improved median survival by 1.4 months, they said. Three doctors at Sloan-Kettering publicized the decision last month in an op-ed article in The New York Times.

Read at The Bulletin
Read at New York Times
Read at Nasdaq


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES